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Abstract
Due to the number of acetaminophen overdoses each year,
the Food and Drug Administration and the National Center
for Prescription Drug Programs made changes and
recommendations regarding the labeling of acetaminophencontaining products. It is important for pharmacists to
understand these changes and to educate patients on the
correct use of these products.
Introduction
Acetaminophen is one of the most commonly used medications in the United States. A 2006 survey showed that during
any given week, 19 percent of adults and 11 percent of children were using acetaminophen-containing products.1 If
taken in excess, acetaminophen can cause liver injury. The
Food and Drug Administration (FDA) estimates that 14 to 21
percent of all acetaminophen overdoses are not intended;
however, some patients may intentionally overdose on
acetaminophen.z Since the 1990s, efforts have been made to
decrease the number of acetaminophen-related liver
injuries, but medical literature continues to show that
acetaminophen-related liver injuries are still a serious public
health problem.3 Recently the FDA and the National Center
for Prescription Drug Programs (NCPDP) have taken actions
to help mitigate this problem. Labeling of prescription
products containing acetaminophen will be changing, and
suggestions for the labeling of over the counter (OTC)
products were proposed as well. With the new labeling
changes to come out within the next few years, pharmacists
can help play a role in overdose prevention by providing
patient counseling and education.
Background
In the years 1998-2003, acetaminophen-related liver injury
was the leading cause of acute liver failure in the United
States.4 Acetaminophen does not harm the liver directly; instead the harm is caused by one of its metabolites.s A small
percentage of acetaminophen is excreted unchanged in the
urine, but the remaining amount is metabolized in the liver.
In adults, approximately 75 percent of acetaminophen is broken down by the liver into inactive metabolites. The rest is
metabolized by CYP2E1 to form N-acetyl-parabenzoquinoneimine (NAPQI). Normally the body rids itself of NAPQI
by binding it with glutathione and excreting it. During an
overdose, the production of NAPQI exceeds the supply of
glutathione causing a toxic buildup of NAPQI. Patients with a
history of chronic alcohol use, binge drinking, or liver disease
may be more prone to liver injury from acetaminophen
because of increased production of toxic metabolites or
decreased clearance of the metabolites.3,6
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Symptoms of acetaminophen overdose vary.s Some patients
appear asymptomatic while others experience GI symptoms
or pain in the upper right quadrant. Initial signs of hepatic
failure such as metabolic acidosis start to occur within 24 to
72 hours of overdose.
Acetaminophen overdose is diagnosed by patient history and
current acetaminophen levels.6 The antidote of choice is
N-acetylcysteine.s N-acetylcysteine is most effective when
administered no more than 8-10 hours after ingestion of
acetaminophen, but may be effective if started within 24
hours.s.6 Treatment is continued until either the patient
shows clinical and laboratory improvement, the patient
receives a liver transplant, or death occurs. Mortality associated with acetaminophen-related acute liver failure is nearly
30 percent and is often due to cerebral edema. If the patient
survives, the liver will typically return to baseline function
within three months.6

Prescription Label Changes
On January 13, 2011, the FDA released information regarding
changes of acetaminophen in prescription combination products. The main focus of the changes included limiting the
amount of acetaminophen to no more than 325 mg in each
tablet or capsule.7 Many acetaminophen overdoses are unintentional and are due to the patient's lack of knowledge
about products containing acetaminophen. The FDA hopes to
prevent these unintentional overdoses by limiting the
amount of acetaminophen in prescription products.3 Furthermore, the FDA also requires an update on the labels of prescription combination acetaminophen products.7 Manufacturers will need to include a boxed warning on the label
about the potential risk for severe liver injury and a warning
regarding the potential for allergic reactions.a There will be a
three-year period for all manufacturers to re-formulate their
products to adhere to these new regulations, with a deadline
in 2014. For a list of prescription drugs that are affected, refer to the following website: http://www.fda.gov/Drugs/
DrugSafety/ucm239821.htm .9
The NCPDP developed a work group to help form standard
best practices and suggestions for prescription labels of
products containing acetaminophen. The NCPDP work group
developed recommendations to improve labels by creating
similarities between OTC and prescription labels. Their goal
is to decrease patient misinterpretation of the label, which
may reduce the occurrence of acetaminophen overdose.
Table 1 shows recommendations made by NCPDP.lO
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OTC Label Changes
At the time of this writing, the FDA's decision did not affect
OTC products, although in May 2011 the FDA Advisory Panel
for Nonprescription Medications released recommendations
for OTC medications (Table 2).
OTC products containing acetaminophen are not officially
affected by the FDA's decision, but McNeil Consumer Healthcare (the manufacturer of Tylenol®) announced changes to
their products in response to the new recommendations that
are expected to occur in 2012. A new maximum daily dose
will be provided for regular strength and extra strength formulations. McNeil Consumer Healthcare also plans on changing their liquid formulations to make one consistent liquid
dose for both children's and infant's Tylenol®. Furthermore,
dosing instructions will be based on age and weight and will
be provided for children as young as six months of age. The
manufacturer hopes these changes will help eliminate medication errors and decrease the chance of accidental acetaminophen overdoses.11
The NCPDP suggests that OTC labeling should change as well
to help patients avoid acetaminophen overdoses. Suggested
label changes include highlighting "acetaminophen" under
the active ingredients portion and adding more caution elements to the warning section.10
Pharmacist Involvement
As members of the FDA met to discuss acetaminophen, they
focused on a quote from Paracelsus, "Everything is a poison.
What differentiates a poison from a remedy is the dose."12
This quote stresses the importance of the pharmacist's role
in educating patients and caregivers about proper dosing and
use of acetaminophen-containing products (Tables 3 and 4).
A government study found that almost 89 million American
adults of various age, race, and economic status suffer from
low health literacy, which refers to ability to make health
decisions and follow treatment instructions. Given the large
number of individuals with low health literacy, it is important for pharmacists to appropriately counsel all patients and
caregivers. This would help minimize the likelihood of negative outcomes such as more serious medical problems, increased medical costs, and more doctor and hospital visits.13
Table 1. NCPDP Recommendations for Prescription
Labeling1°
•

•
•
•
•

Complete spelling of active ingredients in
acetaminophen- containing drugs (avoid use of
the abbreviation "APAP")
Standard acetaminophen use and
liver damage warning label
Prioritize the warning label on packaging
Acetaminophen warning icon on product
to ensure patient awareness
Use plain language principles and patient-centered
labels to increase patient comprehension
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Table 2. Suggestions made by the FDA Advisory Panel
for Nonprescription Medications11
•
•
•
•

One strength ofliquid, chewable, and tablet form
(currently there are 7 different strengths)
Children's dosing instruction begin at 6 months
Dosing based on weight, not just age
Dosing device standards on spoons and cups
with a consistent unit for measuring
(current units include mL, cc, and tsp)

Table 3. Counseling Points For Adult Patients Using
Acetaminophen-containing Products1s
• Do not exceed 4 grams/day
• Do not take multiple acetaminophen-containing
products
• Do not drink alcohol while taking acetaminophencontaining products
• Use has caused severe liver injury and cases of
hypersensitivity reactions
• Report anytime more was taken than directed
• Report adverse events

Table 4. Counseling Points for Advising Parents or
Other Caregivers on Acetaminophen Use in Children
• Do not give multiple medications containing
acetaminophen.16
• Give only as long as necessary; check with the health
care provider if the child needs medication for more
than a few days.16
• Since labels are at an 8th grade reading ability (and
almost half of American adults read below this level),
explain the label and how to calculate and measure
doses.17
Explain:
• appropriate use of measuring devices
• how to measure correct amount
• dosing schedule16
• Contact doctor ifthe infant or child is lethargic or
difficult to wake up.16
• Use weight-based dosing; not to exceed 5 doses per
day. 17
• There are different concentrations in various
preparations.17
Given the anticipated changes to the OTC
products, always confirm the formulation
of the product being used; do not assume
the caregiver has the most current product.a
• Use a single liquid preparation for all infants and
children in a household.17
• Fevers are protective mechanisms and do not always
need treated.17
0

0
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A study surveying patients' knowledge related to acetaminophen recognition, dosing, and toxicity showed the need for
proper counseling by a healthcare provider. Patients (n=284)
19 years or older were questioned about current and/ or recent use of pain, cold, or allergy medications. Out of patients
reporting use, only 25 percent knew the active ingredient.
Less than half of the patients knew that Tylenol® and acetaminophen were synonymous and even fewer knew that
APAP was also an alternative name. Only 13 percent of patients correctly identified three labels as containing Tylenol®.
Although the majority of patients knew the potential harm of
Tylenol®, some thought taking a harmful amount was difficult or impossible. Few patients knew the correct dose and
many patients chose doses at toxic levels.1 4 This study
showed that without appropriate knowledge on terminology,
toxicity, and dosing of acetaminophen, the potential for harm
exists. Counseling and patient education, along with the recently announced changes to strength and labeling of products, are key to reducing the incidence of acetaminophen
overdose.
Multiple studies have shown that acetaminophen overdose
affects children as well. Children do not reach adult levels of
hepatic metabolism and excretion until they are about 12
years old. 16 There have been a few reports of toxicity at
doses of 50-75 mg/kg/day.16
Studies have found that overdoses occurred when teaspoonful quantities of infant drops were given instead of the children's liquid formulation and when regular strength tablets
were given instead of children's chewable tablets.17 In addition, another study was performed to assess the impact of
dosing instruments and parents' ability to correctly use
them. It was observed that parents (n=302) were more likely
to make dosing errors when using a dosing cup compared to
other dosing forms due to confusion of teaspoon versus tablespoon instructions, assumptions that the full cup indicated the unit dose, and lack of eye-level dose verifications.18
Data has shown that there are high rates of errors in dosing
infant acetaminophen, even among parents with adequate
health literacy; a pictogram may be beneficial to educate patients on proper dosing.19
For these reasons, caregivers should be informed about
proper dosing and accurate use of dosing instruments. 10 Parents may consult the pediatrician if the child seems nauseated, vomits, and/or becomes lethargic after consuming
these products. However, by that time, liver injury may have
already occurred.17 Therefore, it is important for caregivers
to know the instructions for dosing and signs of potential
toxicity.
Medicines in My Home (MIMH) is an interactive program
created by the FDA to teach consumers how to properly
choose and use OTC medications. Pharmacists can utilize
these resources or refer their patients to the website: http://
www.fda.gov/Drugs/ResourcesForYou/Consumers/ Buying
UsingMedicineSafely/UnderstandingOver-the-CounterMedicines /
ucm092139.htm.
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Conclusion
Based on the information known about acetaminophen associated hepatotoxicity due to overdose and the FDA's recent
actions regarding acetaminophen labeling, pharmacists
should educate patients and caregivers on these changes and
counsel them on proper use and dosing of acetaminophencontaining products.
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